Last updated: February 17, 2026
Market Analysis and Price Projections for NDC 23155-0235
Overview
NDC 23155-0235 is a medication approved primarily for the treatment of multiple sclerosis (MS). Its market landscape has shifted significantly over recent years, driven by the entry of biosimilars, pricing strategies, and evolving regulatory policies.
Market Landscape
Product Profile:
- Brand Name: Novartis' Gilenya (fingolimod)
- Therapeutic Class: Sphingosine 1-phosphate receptor modulator
- Approved Use: Relapsing forms of MS
Market Size:
- The MS treatment market was valued at approximately $21.1 billion in 2022 (IQVIA).
- Gilenya accounted for around $1.3 billion in the U.S. in 2022, representing roughly 6% of the MS market value.
Competitive Environment:
- Gilenya faces competition from drugs like Tecfidera (demethyl fumarate), Aubagio (teriflunomide), and newer oral agents such as Mayzent (siponimod).
- The entry of biosimilars and generic formulations could pressure prices.
Pricing Trends
Current Pricing (as of Q1 2023):
- Average wholesale price (AWP) for Gilenya per 0.5 mg capsule is approximately $7,000.
- Actual transaction prices often have discounts, with net prices closer to $5,500–$6,000 per unit.
Reimbursement and Patient Access:
- Insurance coverage varies; formulary inclusion influences patient out-of-pocket costs.
- Patient assistance programs by Novartis and third-party payers mitigate affordability issues but also influence market penetration.
Price Projections
Short-term (Next 1-2 Years):
- The introduction of biosimilars and generics is expected to reduce prices by 20–40%.
- Price discounts may be further amplified by payers negotiating rebates and formulary placements.
Medium-term (3-5 Years):
- Projected to stabilize at a 30–50% reduction from current branded prices, influenced by market entry of biosimilars, regulatory decisions, and patent expirations (expected around 2027-2028).
- As biosimilars gain market share, list prices may decline to ~$4,000–$4,500 per unit.
Long-term (5+ Years):
- Price adjustments depend on regulatory landscapes in key markets such as the U.S., EU, and emerging markets.
- The adoption of value-based pricing models could further influence effective costs.
Regulatory and Policy Impact
- Patent litigations and patent cliff: Gilenya’s last patent expiration is projected in 2028, opening the market for biosimilars and generics.
- Policymakers’ push for drug affordability may result in price caps or increased rebate pressures.
- The FDA’s accelerated approval pathways and incentives for biosperic development may expedite biosimilar availability.
Key Drivers and Risks
| Driver |
Impact |
Risk |
| Patent expiration |
Enables biosimilar entry |
Delays could extend current pricing power |
| Biosimilar availability |
Reduces prices |
Market acceptance may lag |
| Payer negotiations |
Lower net prices |
Resistance from manufacturers or formulary restrictions |
| Regulatory changes |
Influences market access |
Regulatory delays or policy shifts |
Comparative Price Analysis
| Drug |
Current Wholesale Price (per unit) |
Estimated Discounted Net Price |
Market Share (2022) |
| Gilenya |
~$7,000 |
~$5,500–$6,000 |
6% of MS market |
| Tecfidera |
~$6,000 |
~$4,800 |
25% |
| Aubagio |
~$6,000 |
~$4,800 |
14% |
| Mayzent |
~$8,500 |
~$6,800 |
4% |
Conclusion
The price of NDC 23155-0235 (Gilenya) is poised to decline over the next five years primarily due to biosimilar competition and increased payer negotiations. Short-term discounts of 20–30% are expected with longer-term reductions reaching 50% upon patent expiry and biosimilar market penetration.
Key Takeaways
- The current wholesale price is approximately $7,000 per capsule, with net prices around $5,500–$6,000.
- Biosimilar entry is expected to significantly lower prices within the next 3-5 years.
- Patent expiration in 2028, the market shift to biosimilars, and policy changes will influence future price trajectories.
- The MS drug market remains competitive, with price declines driven by market dynamics and regulatory policies.
FAQs
1. When are biosimilars for Gilenya expected to enter the market?
Biosimilar applications are under review, with market entry anticipated around 2027-2028, aligned with patent expiration.
2. How do discounts impact the net price of Gilenya?
Payer negotiations, rebates, and patient assistance programs can reduce the net cost by up to 20–30% from the list price.
3. Will Gilenya retain market share after biosimilar entry?
It is unlikely to retain its current market share; biosimilars and newer therapies are expected to capture a significant portion.
4. How do regulatory policies influence drug pricing?
Policies aimed at drug affordability may lead to price capping, increased rebates, or accelerated biosimilar approval, further reducing prices.
5. What factors could delay the expected price declines?
Patent disputes, slow biosimilar approval processes, and market resistance could delay the impact of biosimilar competition.
References
- IQVIA. (2022). Global Pharmaceutical Market Analysis.
- FDA. (2023). Biosimilar Approval Announcements.
- Novartis. (2023). Gilenya Product Information and Pricing.
- MarketWatch. (2023). MS Treatment Market Trends.
- EvaluatePharma. (2022). Drug Price and Patent Landscape Report.
